Haemonetics Corporation cash flow to debt ratio of 23.94% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Haemonetics Corporation's free cash flow has increased 82.83% from $142.45M last year to $260.44M, signaling increasing performance

Haemonetics Corporation's debt to equity ratio is 1.54, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Haemonetics Corporation's debt has increased relative to shareholder equity from 1.49 last year to 1.54 today, signaling weakened financials

Haemonetics Corporation has a net debt to EBITDA ratio of 3.13x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Haemonetics Corporation's interest coverage ratio of 9.77 indicates that earnings with good margin can cover interest payments on company debt

Haemonetics Corporation's profit margin has decreased (-40.80%) in the last year from 12.32% to 7.29%, signaling decreasing performance

Haemonetics Corporation's short-term assets of $834.88M exceed its short-term liabilities of $282.60M

Haemonetics Corporation's return on assets of 4.06% is lower than the 5.00% threshold, indicating inefficient asset utilization

Haemonetics Corporation's return on equity of 11.32%, is lower than 15.00%, indicating bad performance

Haemonetics Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Haemonetics Corporation had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Haemonetics Corporation has positive free cash flow, indicating the company generates cash after capital expenditures

Haemonetics Corporation has a free cash flow yield of 7.70%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Haemonetics Corporation's yearly earnings has decreased -41.97% since last year from $167.68M to $97.31M, signaling decreasing performance

Haemonetics Corporation's yearly revenue has decreased -1.97% since last year from $1.36G to $1.33G, signaling decreasing performance

ROIC 8.69% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Haemonetics Corporation's 3-year revenue CAGR of 4.51% is positive, indicating growing revenue over the past 3 years

Haemonetics Corporation had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Haemonetics Corporation had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Haemonetics Corporation is overvalued relative to its fair value price of 25.16 based on Discounted Cash Flow model

Haemonetics Corporation has an earnings yield of 2.83%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Haemonetics Corporation is overvalued relative to its fair value price of 33.63 based on EBITDA multiple model

Haemonetics Corporation has an EV/EBITDA ratio of 13.96x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Haemonetics Corporation is overvalued relative to its fair value price of 73.71 based on Earnings Fair Value model

Haemonetics Corporation has no meaningful EPS growth rate; PEG ratio cannot be computed.

Haemonetics Corporation has a price-to-book ratio of 4.32x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Haemonetics Corporation has a price-to-sales ratio of 2.58x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue